US company to use virus-like protein nanoparticles as vaccine against coronavirus

An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 Novel Coronavirus. (Reuters)

US biotechnology company Ufovax extended its patented one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology to a vaccine against the coronavirus COVID-19.

The vaccine prototype features SARS-CoV-2 protein spikes protruding from a protein nanoparticle scaffold.

As a virus-like particle (VLP), the nanoparticle vaccine would induce the immune system to rapidly generate antibodies to neutralize (deactivate) the coronavirus, offering a recipient protection against the real SARS-CoV-2 virus, the company said in a statement.

“The 1c-SApNP vaccine platform was invented by Jiang Zhu, PhD, Associate Professor in the Department of Integrative Structural and Computational Biology at Scripps Research. This platform has already delivered promising vaccine candidates to address global health challenges such as HIV, HCV, Ebola, and RSV.”

Over the past two years, Zhu has co-led two NIH-supported projects focusing on SARS-CoV/MERS-CoV vaccine development. After the recent COVID-19 outbreak, Zhu and his team used the nanoparticle platform to create a vaccine against SARS-CoV-2 in less than 60 days.

“I am thrilled about our success in completing this crucial first step toward developing a vaccine against the new coronavirus. We hope to soon begin initial tests to see whether our vaccine can induce an immune response against SARS-CoV-2 in animal models and eventually in clinical trials,” said Dr. Zhu.

“The nanoparticle vaccine consists of self-assembling VLPs made from identical proteins; these proteins are synthesized through the insertion of a single plasmid encoding the relevant gene into a CHO or C1 (DYAI) host cell, followed by one-step expression and two subsequent purifications,” Ufovax added.

Read more:

German researchers to issue coronavirus ‘immunity certificates’ based on antibodies

Chinese study treats five critically ill coronavirus patients with plasma transfusion

Canadian researchers race to design face masks that kill the coronavirus with salt

SHOW MORE
Last Update: Wednesday, 20 May 2020 KSA 10:02 - GMT 07:02
Top